{"id":390644,"date":"2018-06-18T00:00:00","date_gmt":"2018-06-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0014-2018-biopharma-bladder-cancer-current-treatment-physician-insights-us-2018\/"},"modified":"2026-04-23T11:39:30","modified_gmt":"2026-04-23T11:39:30","slug":"cutron0014-2018-biopharma-bladder-cancer-current-treatment-physician-insights-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0014-2018-biopharma-bladder-cancer-current-treatment-physician-insights-us-2018\/","title":{"rendered":"Bladder Cancer | Current Treatment: Physician Insights | US | 2018"},"content":{"rendered":"<p>Treatment of bladder cancer is influenced by a number of factors including disease stage and histology. The swift entry of immune checkpoint inhibitors has transformed the treatment algorithm for bladder cancer; they are becoming entrenched options owing to their tolerability and impressive efficacy. Though platinum-based chemotherapy remains as standard, Merck &#038; Co.&#8217;s\u00a0<abbr title=\"programmed cell death-1\">PD-1<\/abbr>\u00a0inhibitor, Keytruda, and Roche\/Genentech&#8217;s\u00a0<abbr title=\"programmed death-ligand 1\">PD-L1<\/abbr>\u00a0inhibitor, Tecentriq, are revolutionizing the treatment algorithm for advanced patients ineligible to receive standard cisplatin-based therapy.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What percentage of non-muscle-invasive bladder cancer patients receives maintenance\u00a0<abbr title=\"bacillus Calmette-Gu\u00e9rin\">BCG<\/abbr>, and how does this vary by stage and histologic grade?<\/li>\n<li>What is the uptake of immune checkpoint inhibitors in the United States? How are immune checkpoint inhibitors faring against older therapies (e.g., platinum-based chemotherapy)?<\/li>\n<li>How do drug-treatment rates vary across key patient populations?<\/li>\n<li>What are the main drivers and obstacles for treatment with key brands for unresectable locally advanced or metastatic bladder cancer?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Current Treatment: Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand usage so you can understand each brand\u2019s performance and improve or defend your competitive position.<\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Survey of 100 U.S. medical oncologists\u00a0fielded in April 2018.<\/p>\n<p><strong>Key companies:<\/strong>\u00a0Merck &#038; Co.,\u00a0Roche\/Genentech, Bristol Meyers Squibb, AstraZeneca, Merck KGaA\/Pfizer<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0Keytruda, Tecentriq, Opdivo, Imfinzi, Bavencio<\/p>\n","protected":false},"template":"","class_list":["post-390644","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-bladder-cancer","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390644\/revisions"}],"predecessor-version":[{"id":576728,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390644\/revisions\/576728"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}